Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
68 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Alopecia - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Alopecia - Pipeline Review, H1 2015', provides an overview of the Alopecia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Alopecia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alopecia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Alopecia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Alopecia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Alopecia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Alopecia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Alopecia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Alopecia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Alopecia Overview 8 Therapeutics Development 9 Pipeline Products for Alopecia - Overview 9 Pipeline Products for Alopecia - Comparative Analysis 10 Alopecia - Therapeutics under Development by Companies 11 Alopecia - Therapeutics under Investigation by Universities/Institutes 13 Alopecia - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Alopecia - Products under Development by Companies 17 Alopecia - Products under Investigation by Universities/Institutes 18 Alopecia - Companies Involved in Therapeutics Development 19 AndroScience Corporation 19 Bristol-Myers Squibb Company 20 C3 Jian, Inc 21 Follicum AB 22 Kuhnil Pharmaceutical Co., Ltd. 23 Lee's Pharmaceutical Holdings Limited 24 Panacea Biotec Limited 25 ProCertus BioPharm Inc. 26 Taisho Pharmaceutical Co., Ltd. 27 Tigo GmbH 28 Vida Therapeutics Inc. 29 Alopecia - Therapeutics Assessment 30 Assessment by Monotherapy Products 30 Assessment by Target 31 Assessment by Mechanism of Action 33 Assessment by Route of Administration 35 Assessment by Molecule Type 37 Drug Profiles 39 abatacept (recombinant) - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 ASCJ-9 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 calcitriol - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 DHL-HisZnNa - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 interferon beta-1b - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 KI-1104 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 KI-1105 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Peptide for Alopecia - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Peptide for Alopecia and Chemotherapy Effects - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 ProDermaCel - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Recombinant Peptides for Alopecia - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Recombinant Proteins to Antagonize IFN-Gamma Receptor for Alopecia Areata and Graft Arteriosclerosis - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Small Molecule to Inhibit ALK5 for Alopecia and Fibrosis - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Small Molecules to Activate P2Y5 Receptor for Alopecia - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Small Molecules to Inhibit Plasminogen Activator Inhibitor-1 for Thromboembolic Disease, PCOS and Alopecia - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 V-2248 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 ZK-003 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Alopecia - Recent Pipeline Updates 60 Alopecia - Dormant Projects 63 Alopecia - Discontinued Products 65 Alopecia - Product Development Milestones 66 Featured News & Press Releases 66 Jul 23, 2012: Berg Pharma Launches Clinical Trial On BPM 31543 For Prevention Of Chemotherapy-induced Alopecia 66 Appendix 67 Methodology 67 Coverage 67 Secondary Research 67 Primary Research 67 Expert Panel Validation 67 Contact Us 67 Disclaimer 68
List of Tables Number of Products under Development for Alopecia, H1 2015 9 Number of Products under Development for Alopecia - Comparative Analysis, H1 2015 10 Number of Products under Development by Companies, H1 2015 12 Number of Products under Investigation by Universities/Institutes, H1 2015 13 Comparative Analysis by Late Stage Development, H1 2015 14 Comparative Analysis by Clinical Stage Development, H1 2015 15 Comparative Analysis by Early Stage Development, H1 2015 16 Products under Development by Companies, H1 2015 17 Products under Investigation by Universities/Institutes, H1 2015 18 Alopecia - Pipeline by AndroScience Corporation, H1 2015 19 Alopecia - Pipeline by Bristol-Myers Squibb Company, H1 2015 20 Alopecia - Pipeline by C3 Jian, Inc, H1 2015 21 Alopecia - Pipeline by Follicum AB, H1 2015 22 Alopecia - Pipeline by Kuhnil Pharmaceutical Co., Ltd., H1 2015 23 Alopecia - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015 24 Alopecia - Pipeline by Panacea Biotec Limited, H1 2015 25 Alopecia - Pipeline by ProCertus BioPharm Inc., H1 2015 26 Alopecia - Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2015 27 Alopecia - Pipeline by Tigo GmbH, H1 2015 28 Alopecia - Pipeline by Vida Therapeutics Inc., H1 2015 29 Assessment by Monotherapy Products, H1 2015 30 Number of Products by Stage and Target, H1 2015 32 Number of Products by Stage and Mechanism of Action, H1 2015 34 Number of Products by Stage and Route of Administration, H1 2015 36 Number of Products by Stage and Molecule Type, H1 2015 38 Alopecia Therapeutics - Recent Pipeline Updates, H1 2015 60 Alopecia - Dormant Projects, H1 2015 63 Alopecia - Dormant Projects (Contd..1), H1 2015 64 Alopecia - Discontinued Products, H1 2015 65
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
